Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.53 |
| ▸ | FAP | Q12884 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | LAP3 | P28838 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9651237 | 0.84 | — | — | |
| SCHEMBL9651230 | 0.84 | — | — | |
| SCHEMBL19503059 | 0.83 | DPP4 (0.53) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL21614009 | 0.83 | DPP4 (0.53) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL19522543 | 0.83 | DPP4 (0.53) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL11100606 | 0.82 | DPP4 (0.50) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL30457093 | 0.81 | DPP4 (0.52) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL29871436 | 0.81 | DPP4 (0.52) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL20834998 | 0.81 | DPP4 (0.52) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL30463284 | 0.81 | DPP4 (0.52) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246486-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-2859009-B1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170190737-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190737-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | DPP4 238/4885DPP8 182/4885DPP9 323/4885 |
| US-10246486-B2 | Macrocyclic inhibitors of flaviviridae viruses | HAVCR2, ZC3HAV1, HCCS | DPP4 238/4885DPP8 182/4885DPP9 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.